ArticleScientific reports2025
Biosynthesis and health promoting traits of green synthesized cobalt oxide nanoparticles.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Remedial applications of biosynthesized metal oxide nanoparticles against pathogenic microorganisms.Discover nano · 2026Review
- Bio-generated CoO-NPs from Salvia officinalis: a promising tool against ESBL-producing bacteria.Scientific reports · 2026Article
- Multifunctional hierarchical NiScientific reports · 2026Article
- Sustainable plant mediated synthesis of cobalt oxide nanoparticles using Uraria picta extract with enhanced biological activity.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Nanomedical applications have increased significantly. This work aimed to fabricate and characterize cobalt oxide nanoparticles (CoOnps) synthesized biologically via aqueous Alhagi maurorum extract and evaluate their cytotoxic and antimicrobial impacts. Green-synthesized CoOnps were prepared and analyzed using UV-Vis spectrophotometer UV-vis, Scanning electron microscopy (SEM), Transmission electron microscopy TEM, Energy dispersive X-ray analysis EDAX, Fourier transform infrared, FTIR, and X-ray diffraction (XRD). In vitro traits of green-synthesized CoOnps were studied on ovarian cancer cells (SKOV3) using a Sulforhodamine B (SRB) method. The cytotoxic effect and IC50 were estimated. Moreover, concentrations of 10, 30, 40, 70, 100, 200, 300, 400 and 500 μg/mL CoOnps were applied to investigate their antimicrobial effect against Listeria, Staphylococcus aureus and Streptococcus as gram +ve pathogenic bacteria, Bifidobacterium bifidum 2203, Bifidobacterium bifidum LMG 10,645, Bifidobacterium breve LMC 017, Bifidobacterium angulatum 2238 and Bifidobacterium longum ATCC 15,707 as probiotics, E. coli as gram -ve bacterial model and yeast strain Candida albicans. CoOnps showed anti-ovarian cancer effects at 24.02 μg/mL. Furthermore, it exerted antimicrobial activity versus Listeria, Streptococcus, S. aureus, and E. coli were 31.66 ± 0.88, 24.33 ± 2.08, 25.66 ± 0.33, and 33.00 ± 6.08; however, they did not suppress the growth of Candida albicans and all tested Bifidobacterial strains up to concentrations of 500 μg/mL with significant difference compared to all concentrations p < 0.05. Green synthesis of CoOnps is a low-cost, eco-friendly and easily prepared method. Its impressive features as cytotoxic SKOV3, a cell line ovarian cancer and antibacterial effect for some gram +ve and -ve bacteria, besides maintaining probiotics, could candidate them as competitive agents for medical, pharmacological, agricultural and food applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.